Icandra 50 Mg 30 Tablets

Icandra 50 Mg 30 Tablets

Description:

Icandra 50 mg 30 tablets is an oral anti-diabetic prescription medicine containing vildagliptin, a dipeptidyl peptidase-4 (dpp-4) inhibitor. It is used as part of a comprehensive diabetes care plan to improve blood glucose control in adults with type 2 diabetes mellitus. Icandra works by enhancing the body’s own ability to regulate blood sugar levels, especially after meals, and is usually used in combination with diet, exercise, and sometimes other anti-diabetic medicines such as metformin or insulin. This product is intended for adult patients and should be used under medical supervision.

Indications:

• Management of type 2 diabetes mellitus in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
• Adjunctive therapy in combination with other oral anti-diabetic agents (such as metformin, sulfonylureas, thiazolidinediones) when these alone do not provide adequate glycemic control (indication details may vary by local product label; consult prescribing information).
• Helps reduce elevated fasting and postprandial (after-meal) blood glucose levels.
• Supports improvement of overall glycemic control (for example, lowering hba1c) as part of a long-term diabetes management plan.

Active Ingredients / Key Components:

• Vildagliptin – 50 mg per tablet (dpp-4 inhibitor anti-diabetic agent).
• Excipients: Full list of inactive ingredients (such as fillers, binders, coating agents, colorants) is not available in the provided information. Please refer to the official package insert for the complete excipient list.

Dosage & Administration / How to Use:

• Use only as prescribed by your physician or diabetologist. Do not change your dose without medical advice.
• Typical adult dosing for vildagliptin in many products is 50 mg once or twice daily, depending on whether it is used alone or in combination with other anti-diabetic medicines. The exact recommended dose, frequency, and regimen for Icandra 50 mg must be confirmed from the official Egyptian product leaflet and your doctor’s instructions.
• Tablets are taken orally with water and can generally be taken with or without food, unless your doctor advises otherwise.
• Take the medicine at the same time(s) each day to maintain steady blood levels and optimal glycemic control.
• If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double the dose to make up for a missed tablet.
• Continue following a balanced diabetic diet, regular physical activity, and blood glucose monitoring as advised by your healthcare provider.
• Regular follow-up visits and blood tests (including liver function tests and hba1c) may be required to monitor response and safety.

Clinical Benefits:

• Helps improve glycemic control in adults with type 2 diabetes by enhancing glucose-dependent insulin secretion and reducing glucagon levels.
• Targets both fasting and postprandial blood glucose levels, supporting more stable day-long blood sugar control.
• Glucose-dependent mechanism of action is associated with a lower intrinsic risk of hypoglycemia compared with some other secretagogues when used appropriately (risk may increase when combined with sulfonylureas or insulin).
• Can be used in combination with other anti-diabetic therapies, allowing individualized treatment regimens tailored to patient needs.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to vildagliptin or any of the excipients in the formulation.
• Not indicated for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Use with caution in patients with moderate or severe renal impairment or hepatic impairment; dose adjustment or alternative therapy may be required. Liver function monitoring is often recommended with vildagliptin-containing products.
• Cases of hepatic dysfunction, including hepatitis, have been reported with vildagliptin; discontinue treatment if liver enzyme elevations persist or worsen, or if signs of liver injury (such as jaundice, dark urine, persistent nausea) appear.
• Pancreatitis has been reported with dpp-4 inhibitors. If you experience severe, persistent abdominal pain (with or without vomiting), stop the medicine and seek medical attention immediately.
• May increase risk of hypoglycemia when used in combination with sulfonylureas or insulin; your doctor may adjust doses of concomitant medicines.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Use during pregnancy or lactation should only occur if clearly needed and under medical supervision.
• Inform your doctor about all other medicines you are taking, including over-the-counter products and herbal supplements, to avoid potential interactions.
• Not intended to diagnose, treat, cure, or prevent any disease without proper medical supervision and prescription.
• Keep out of reach of children.

Side Effects:

• Common side effects reported with vildagliptin-containing products may include headache, dizziness, mild gastrointestinal disturbances (such as nausea, constipation, or diarrhea), and upper respiratory tract infections. Frequency and intensity can vary by patient and by combination therapy.
• When used with other anti-diabetic agents (such as sulfonylureas or insulin), hypoglycemia (low blood sugar) may occur, presenting with symptoms like sweating, tremor, hunger, palpitations, confusion, or dizziness.
• Less common but serious adverse effects may include pancreatitis (severe abdominal pain radiating to the back, vomiting), liver function abnormalities or hepatitis (jaundice, dark urine, fatigue, abdominal pain), and hypersensitivity reactions (rash, itching, swelling, difficulty breathing).
• If you experience signs of severe allergic reaction, pancreatitis, marked liver problems, or any other unusual or severe symptoms, stop taking the medicine and seek immediate medical attention.
• Not all possible side effects are listed here. Refer to the official patient information leaflet and consult your healthcare provider for complete safety information.

Storage Instructions:

Store in a cool, dry place away from direct sunlight and moisture. Keep the blister pack or container tightly closed. Do not store above the temperature specified on the original packaging (exact temperature range is not available in the provided information; please refer to the product carton). Keep out of reach of children.

Specifications:

• Product type: Prescription anti-diabetic medicine (oral).
• Active ingredient strength: vildagliptin 50 mg per tablet.
• Form: film-coated tablets.
• Pack size: 30 tablets per pack.
• Intended users: adults with type 2 diabetes mellitus, under physician supervision.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.